Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNMT1 | P26358 | 9/20 | 1.00 |
| ▸ | DNMT3B | Q9UBC3 | 4/20 | 1.00 |
| ▸ | FPR2 | P25090 | 7/20 | 0.83 |
| ▸ | NNMT | P40261 | 1/20 | 0.64 |
| ▸ | WDR5 | P61964 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | RBBP5 | Q15291 | 1/20 | 0.63 |
| ▸ | DPY30 | Q9C005 | 1/20 | 0.63 |
| ▸ | ASH2L | Q9UBL3 | 1/20 | 0.63 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.62 |
| ▸ | SETD2 | Q9BYW2 | 1/20 | 0.62 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.62 |
| ▸ | RNMT | O43148 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23610159 | 1.00 | DNMT1 (1.00) | DNMT1DNMT3BFPR2NNMTWDR5 | |
| SCHEMBL23610153 | 1.00 | DNMT1 (1.00) | DNMT1DNMT3BFPR2NNMTWDR5 | |
| SCHEMBL23624396 | 0.94 | DNMT1 (1.00) | DNMT1DNMT3BFPR2NNMTWDR5 | |
| SCHEMBL23610064 | 0.94 | DNMT1 (1.00) | DNMT1DNMT3BFPR2NNMTWDR5 | |
| SCHEMBL23610063 | 0.94 | DNMT1 (1.00) | DNMT1DNMT3BFPR2NNMTWDR5 | |
| SCHEMBL23624404 | 0.94 | DNMT1 (1.00) | DNMT1DNMT3BFPR2NNMTWDR5 | |
| SCHEMBL23610115 | 0.93 | DNMT1 (1.00) | DNMT1DNMT3BFPR2NNMTWDR5 | |
| SCHEMBL23624388 | 0.93 | DNMT1 (1.00) | DNMT1DNMT3BFPR2NNMTWDR5 | |
| SCHEMBL23610112 | 0.93 | DNMT1 (1.00) | DNMT1DNMT3BFPR2NNMTWDR5 | |
| SCHEMBL23624599 | 0.93 | DNMT1 (1.00) | DNMT1DNMT3BFPR2NNMTWDR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11518779-B2 | Inhibitors of DNMT1 as anticancer therapeutic agents | VICTORIA LINK LIMITED (NZ) | 2022-12-06 | — | — | US | disclosed |
| US-20210206795-A1 | INHIBITORS OF DNMT1 AS ANTICANCER THERAPEUTIC AGENTS | VICTORIA LINK LTD (NZ) | 2021-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11518779-B2 | Inhibitors of DNMT1 as anticancer therapeutic agents | DNMT1, DNMT3A, DNMT3B | DNMT1 1/4885DNMT3B 3/4885FPR2 4795/4885 |
| US-20210206795-A1 | INHIBITORS OF DNMT1 AS ANTICANCER THERAPEUTIC AGENTS | DNMT1, DNMT3B, DNMT3A | DNMT1 1/4885DNMT3B 2/4885FPR2 4833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.